[go: up one dir, main page]

WO2004006962A3 - Compose de liaison au facteur tissulaire - Google Patents

Compose de liaison au facteur tissulaire Download PDF

Info

Publication number
WO2004006962A3
WO2004006962A3 PCT/DK2003/000481 DK0300481W WO2004006962A3 WO 2004006962 A3 WO2004006962 A3 WO 2004006962A3 DK 0300481 W DK0300481 W DK 0300481W WO 2004006962 A3 WO2004006962 A3 WO 2004006962A3
Authority
WO
WIPO (PCT)
Prior art keywords
factor
tissue factor
viia
compounds
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2003/000481
Other languages
English (en)
Other versions
WO2004006962A2 (fr
Inventor
Soeren E Bjoern
Else Marie Nicolaisen
Thomas D Steenstrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP03763617A priority Critical patent/EP1523504A2/fr
Priority to AU2003242507A priority patent/AU2003242507A1/en
Publication of WO2004006962A2 publication Critical patent/WO2004006962A2/fr
Publication of WO2004006962A3 publication Critical patent/WO2004006962A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des nouveaux composés qui se lient au facteur tissulaire (FT), inhibent son activité et participent indirectement à la réponse immunitaire cytolytique.
PCT/DK2003/000481 2002-07-12 2003-07-09 Compose de liaison au facteur tissulaire Ceased WO2004006962A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03763617A EP1523504A2 (fr) 2002-07-12 2003-07-09 Compose de liaison au facteur tissulaire
AU2003242507A AU2003242507A1 (en) 2002-07-12 2003-07-09 A tissue factor binding immunoconjugate comprising factor viia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201099 2002-07-12
DKPA200201099 2002-07-12

Publications (2)

Publication Number Publication Date
WO2004006962A2 WO2004006962A2 (fr) 2004-01-22
WO2004006962A3 true WO2004006962A3 (fr) 2004-03-18

Family

ID=30011019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000481 Ceased WO2004006962A2 (fr) 2002-07-12 2003-07-09 Compose de liaison au facteur tissulaire

Country Status (3)

Country Link
EP (1) EP1523504A2 (fr)
AU (1) AU2003242507A1 (fr)
WO (1) WO2004006962A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004022800D1 (de) * 2003-05-06 2009-10-08 Syntonix Pharmaceuticals Inc Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE485052T1 (de) * 2006-04-07 2010-11-15 Novo Nordisk Healthcare Ag Kovalenter faktor vii-gewebefaktor-komplex
RU2375449C2 (ru) * 2007-03-29 2009-12-10 Нейрок Фарма ЛЛС КОДИРУЮЩАЯ ДНК (кДНК) ДЛЯ ПОЛУЧЕНИЯ ВИРУСОПОДОБНЫХ ЧАСТИЦ ВИРУСА ГЕПАТИТА С, СПОСОБ ПОЛУЧЕНИЯ ВИРУСОПОДОБНЫХ ЧАСТИЦ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
WO2011073235A1 (fr) * 2009-12-18 2011-06-23 Csl Ltd. Procédé de purification de polypeptides
EP2763693A4 (fr) 2011-10-06 2015-12-09 Hanmi Science Co Ltd Dérivés du facteur vii et viia de coagulation sanguine, conjugués et complexes comprenant ceux-ci, et leur utilisation
CN104774269B (zh) * 2013-08-16 2016-02-24 安源生物科技(上海)有限公司 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途
CN103599527A (zh) * 2013-08-16 2014-02-26 安源生物科技(上海)有限公司 包含改良型人凝血因子FVII-Fc融合蛋白的药物组合物
WO2017015582A1 (fr) * 2015-07-22 2017-01-26 Iconic Therapeutics, Inc. Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
US20200352996A1 (en) * 2017-09-27 2020-11-12 Ohio State Innovation Foundation Tissue factor-targeting car-nk and car-t cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012800A1 (fr) * 1994-10-24 1996-05-02 Zymogenetics, Inc. Facteur vii modifie
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires
WO2001021661A1 (fr) * 1999-09-20 2001-03-29 Novo Nordisk A/S INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012800A1 (fr) * 1994-10-24 1996-05-02 Zymogenetics, Inc. Facteur vii modifie
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires
WO2001021661A1 (fr) * 1999-09-20 2001-03-29 Novo Nordisk A/S INHIBITEUR BIVALENT DU COMPLEXE FVIIa/TF/FXa

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SWALL accession no. Q96PQ8, 98% identity in 641aa overlap; XP002262742 *
ZHIWEI HU ET AL: "Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy", PNAS, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9221 - 9225, XP002262741 *
ZHIWEI HU ET AL: "Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer", PNAS, vol. 98, no. 21, 9 October 2001 (2001-10-09), pages 12180 - 12185, XP002262739 *
ZHIWEI HU ET AL: "Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model", PNAS, vol. 96, no. 14, 6 July 1999 (1999-07-06), pages 8161 - 8166, XP002262740 *

Also Published As

Publication number Publication date
AU2003242507A8 (en) 2004-02-02
AU2003242507A1 (en) 2004-02-02
EP1523504A2 (fr) 2005-04-20
WO2004006962A2 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004052280A3 (fr) Composes anti-angiogenique et utilisations de ceux-ci dans le traitement du cancer
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2004046120A3 (fr) Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004080423A3 (fr) Composes de 7-amino- isoindolyle et leurs utilisations pharmaceutiques
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006106326A8 (fr) Heterocycles substitues et leur utilisation en tant qu’inhibiteurs de la chk1, de la pdk1 et de la pak
WO2006037024A3 (fr) Sels de decitabine
WO2007064931A3 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
WO2006113864A3 (fr) Composes d'oxindole et leurs utilisations comme agents therapeutiques
WO2006025991A3 (fr) Composes d'isoindoline et methodes de production et d'utilisation desdits composes
WO2006034154A3 (fr) Sels de 5-azacytidine
WO2004066918A3 (fr) Composition cosmetique longue tenue
WO2009017369A3 (fr) Compositions contenant des dérivés de dibenzo-p-dioxine permettant de protéger la peau et de soulager les maladies de peau
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2008057512A3 (fr) Imidazopyrazines comme inhibiteurs de protéines kinases
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2004006962A3 (fr) Compose de liaison au facteur tissulaire
WO2005009460A3 (fr) Composition pharmaceutique comportant l'activine a, l'alk-4 ou leurs derives pour le traitement des troubles ophtalmiques ou du cancer
WO2007002884A3 (fr) 4-fluoro-piperidines antagonistes du canal calcium de type t
WO2006098969A3 (fr) Antagonistes de canaux calciques de type t a base de quinazolinone
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2006009525A3 (fr) Peptides de liaison specifiques de l'exopolysaccharide mucoide de p. aeruginosa
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2006057945A3 (fr) Derives pyridyle 2,3,4,6-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003763617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003763617

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003763617

Country of ref document: EP